DIGNITY Trial for RCW Breast Cancer

Added by MultiVu Subscribe 459
Published 6 Oct 2009
123
••• More
Report video
0 0
You have already voted for this video.
Celsion Corporation (NASDAQ:CLSN) announced today initiation of a nationwide enrollment program in its pivo...
Celsion Corporation (NASDAQ:CLSN) announced today initiation of a nationwide enrollment program in its pivotal Phase I/II DIGNITY clinical trial evaluating the use of ThermoDox® in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer. In early studies, conducted at Duke University Medical Center, investigators report that ThermoDox® has demonstrated significant promise in treating this highly aggressive disease.

To view Multimedia News Release, go to 
http://www2.prnewswire.com/mnr/celsion/39944/
Categories: News & Events
Show moreShow less
Report this video as: